Valuation: Medtronic, Inc.

Market Cap 114B 100B 94.24B 86.16B 161B 10,942B 162B 1,132B 439B 5,579B 429B 420B 18,087B P/E 2027 *
18.9x
P/E 2028 * 17.5x
Enterprise Value 135B 119B 112B 102B 191B 12,962B 192B 1,341B 520B 6,609B 508B 497B 21,427B EV / Sales 2027 *
3.46x
EV / Sales 2028 * 3.3x
Free-Float
99.6%
Yield 2027 *
3.15%
Yield 2028 * 3.38%
Manager TitleAgeSince
Chief Executive Officer 56 27/04/2020
Director of Finance/CFO 56 03/03/2025
Chief Tech/Sci/R&D Officer 55 01/09/2020
Director TitleAgeSince
Director/Board Member 66 26/01/2015
Director/Board Member 64 01/01/2013
Director/Board Member 70 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%-0.03%-23.67%+4.85% 179B
-0.03%-3.95%-6.93%+11.43% 114B
+0.24%+1.24%+1.59%+67.32% 59.59B
-0.47%+0.19%-2.32%-31.88% 49.72B
+2.37%+3.35%+10.35%+49.24% 47.75B
-0.64%-0.70%+29.36%+1.46% 33.11B
-0.74%+5.57% - - 30.09B
-0.71%+2.09%+43.98%-0.36% 26.45B
+4.96%+10.05%+19.03%-4.85% 22.79B
Average +0.36%+1.10%+8.92%+12.15% 62.53B
Weighted average by Cap. -0.18%+0.09%-3.73%+12.92%

Financials

2027 *2028 *
Net sales 39.06B 34.28B 32.23B 29.47B 55.06B 3,742B 55.47B 387B 150B 1,908B 147B 143B 6,185B 40.4B 35.46B 33.33B 30.47B 56.94B 3,870B 57.36B 400B 155B 1,973B 152B 148B 6,396B
Net income 6.04B 5.3B 4.98B 4.56B 8.51B 579B 8.58B 59.85B 23.2B 295B 22.68B 22.18B 956B 6.5B 5.71B 5.37B 4.91B 9.17B 623B 9.24B 64.46B 24.99B 318B 24.43B 23.89B 1,030B
Net Debt 21.09B 18.51B 17.4B 15.91B 29.73B 2,020B 29.95B 209B 81.02B 1,030B 79.2B 77.46B 3,340B 19.18B 16.84B 15.83B 14.47B 27.04B 1,838B 27.24B 190B 73.7B 937B 72.04B 70.46B 3,038B
Logo Medtronic, Inc.
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (25%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (19%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (18.1%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - cranial and spinal technologies (14.8%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.7%); - diabetes management (8.2%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.7%): neurostimulation and pumped medication administration products, diagnostic tools, etc. ; - other (0.5%). Net sales are distributed geographically as follows: Ireland (0.3%), the United States (51.2%) and other (48.5%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-